对拉米夫定耐药的慢性乙肝患者面临着病情恶化甚至死亡的危险。
Patients with chronic hepatitis B developing lamivudine resistance are at high risk of disease progression and death.
目的探讨国产阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎的疗效及安全性。
ObjectiveTo evaluate the efficacy and safety of domestic adefovir dipivoxil in patients with hepatitis B resistant to lamivudine.
目的了解拉米夫定耐药与HBV基因型及HBV基本核心启动子(BCP)突变之间的关系。
Objective To investigate the relationship of HBV Lumivudine resistant and HBV genotypes and basic core promoter (BCP) mutation.
邓洪，顾琳，赵志新， 张晓红，彭晓谋，高志良探讨慢性乙型肝炎患者拉米夫定耐药后出现肝功能衰竭的危险因素。
To investigate the risk factors of liver failure due to lamivudine resistance in the patients with chronic hepatitis B.
目的定量分析拉米夫定治疗不同时期耐药突变的变化规律，为及时调整治疗方案提供依据。
Objetive to analysis the regulation of lamivudine-resistant mutations quantitatively in the different therapeutic periods, and to provide the evidences for therapeutic regimen adjustment.
拉米夫定副作用小、早期应用效果显著，但易发生耐药。
Lamivudine has no side effects and is quite potent in the early stage but it is associated with a very high rate of resistance.
拉米夫定副作用小、早期应用效果显著，但易发生耐药。
Lamivudine has no side effects and is quite potent in the early stage but it is associated with a very high rate of resistance.
应用推荐